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pared from four resource categories: chemotherapy acquisition,
drug administration, hospitalisation associated with adverse
events, and other medical resources. Italian health care unit costs
were obtained from published sources. RESULTS: Lowest treat-
ment costs were incurred by the Gem/Cis group (8092€), fol-
lowed by the Vin/Cis and Pac/Carbo groups (9320€ and 11,203€
respectively). The cost difference between the Gem/Cis and
Pac/Carbo regimens was due to the difference in chemotherapy
acquisition costs (3732€), which offset the increased costs for
drug administration (499€) and other medical resources (524€)
in the Gem/Cis group. The overall per-patient cost saving for
Gem/Cis versus Vin/Cis (1227€) was primarily due to reduced
hospitalisations for adverse events (2223€) despite the increased
acquisition costs for Gem/Cis (1422€). CONCLUSIONS: Based
on data collected during a randomised clinical trial, ﬁrst-line use
of Gem/Cis offers potential cost savings compared to other plat-
inum-based third-generation agent combinations in the treat-
ment of advanced NSCLC in Italy. Since these savings relate
primarily to chemotherapy acquisition and hospitalisation costs
due to adverse events, they are likely to be transferred to the
community setting.
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OBJECTIVE: As the prognosis of non-small cell lung cancer
(NSCLC) patients after ﬁrst and second line treatment remains
poor, new targeted strategies in third-line treatment are of high
interest. This study estimates the cost-effectiveness of geﬁtinib
compared to Best Supportive Care (BSC) in the Dutch health care
setting. METHODS: A Markov model was designed to evaluate
the lifetime clinical and economic outcomes of geﬁtinib treat-
ment and BSC. The model was calibrated using clinical data from
randomized clinical studies, a Delphi panel (n = 10), patient chart
analysis and literature for costs data. The analysis was performed
from a societal perspective for a hypothetical cohort of advanced
NSCLC patients, who have failed two chemotherapy regimens.
Only direct costs related to the treatment of severe adverse
events, radiotherapy, evaluation of disease progression and ter-
minal care were considered. The time horizon related to mor-
tality, estimated the costs from start of therapy until death. Both
costs and effects were discounted at 4% pa. RESULTS: With an
assumed difference in survival of 2.45 months between geﬁtinib
and BSC, the model predicts survival of 0.573 life years (LY) for
BSC and 0.790 LY for geﬁtinib. Total costs related to BSC and
geﬁtinib treatment until death are 8444€ and 15,272€ respec-
tively. The average cost-effectiveness ratio of geﬁtinib is higher
than BSC (19,326€/LY versus 14,745€/LY). The incremental
cost-effectiveness ratio of geﬁtinib compared to BSC is 31,380€
per LYG. Applying the threshold proposed by the Institute for
Medical Technology Assessment for disease with highest burden
(45,000€/QALY), geﬁtinib is cost-effective in 73% of advanced
NSCLC patients compared to BSC in third-line therapy. CON-
CLUSION: In addition to its convenient oral administration, its
favorable tolerability proﬁle, geﬁtinib is cost-effective compared
to not only BSC but also compared to heart or liver transplan-
tations. “Iressa” is a trademark of the AstraZeneca group of
companies.
PCN20
COSTS OF TREATING ADVANCED NON-SMALL-CELL LUNG
CANCER IN SPAIN USING GEMCITABINE IN COMBINATION
WITH CISPLATIN: A COMPARISON WITH OTHER 2ND
GENERATION NOVEL AGENTS
Kielhorn A1, Dilla T2, Stynes G3,Tilden D3, Bhalla S1
1Eli Lilly, Windlesham, Surrey, UK; 2Eli Lilly, Madrid, Spain; 3M-TAG
Limited, Hammersmith, UK
OBJECTIVES: To evaluate the costs in Spain of treating
advanced non-small-cell lung cancer (NSCLC) with gemcitabine
plus cisplatin (Gem/Cis) in comparison with other platinum-
based combination chemotherapy regimens, and to compare the
ﬁndings with previously published cost analyses. METHODS: A
retrospective economic analysis was conducted based on medical
resource utilisation in a randomised controlled trial (Scagliotti 
et al. 2002), which found that Gem/Cis demonstrated compara-
ble efﬁcacy to paclitaxel/carboplatin (Pac/Carbo) and vinorel-
bine/cisplatin (Vin/Cis) regimens in 612 patients with advanced
NSCLC. Treatment costs were compared across four main
resource categories: chemotherapy acquisition, drug administra-
tion, hospitalisation episodes, and other medical resources.
Spanish Health Care unit costs were drawn from published lit-
erature and public sources. Results were compared with those
published by Schiller et al. (2004). RESULTS: The mean total
treatment-related costs of Gem/Cis were 5578€ per patient,
which was lower than those seen with Pac/Carbo (11,541€) or
Vin/Cis (6084€). Chemotherapy acquisition was the major cost
driver for Gem/Cis (63% of total costs) and Pac/Carbo (90% of
total costs), but other component costs, especially hospitalisa-
tions, were considerable for the Vin/Cis regimen (36% of total
costs). The total costs per patient are comparable to those
reported for Spain by Schiller et al. (2004) with calculations
based on Comella et al. (2000) (Gem/Cis 4072€; Vin/Cis 4899€)
and Schiller et al. (2002) (Gem/Cis 5082€; Pac/Carbo 840€),
trials employing different dosing schedules. CONCLUSIONS:
Cost-minimisation analyses based on chemotherapy and
resource utilisation in randomised controlled clinical trials
demonstrate that Gem/Cis has lower total treatment costs from
the perspective of the Spanish national health system than
Pac/Carbo and Vin/Cis for the treatment of advanced NSCLC.
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OBJECTIVE: To assess the cost-effectiveness of geﬁtinib
(“Iressa”) compared to BSC in patients with refractory advanced
NSCLC in the UK National Health Service (NHS). METHODS:
A probabilistic model was developed to assess the cost-
effectiveness (and associated uncertainty) of geﬁtinib compared
with BSC in patients with refractory advanced NSCLC in the UK
NHS. Efﬁcacy data were drawn from two independent sources:
data for geﬁtinib were derived from IDEAL II (patients refrac-
tory to platinum and docetaxel) and data for BSC were derived
from a literature review (BSC arm of a randomised controlled
trial in second-line advanced NSCLC). Cost data were collected
from the perspective of the UK NHS. In the absence of a UK
price for geﬁtinib, the pre-approval sales price in France (1950€)
was converted into UK prices (approximately £1300). Resource
utilisation and cost data for geﬁtinib were derived from pub-
